Nefiracetam

From Self-sufficiency
Revision as of 00:09, 17 September 2010 by 70.124.75.191 (Talk)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Nefiracetam
150px
150px
Systematic (IUPAC) name
N-(2,6-dimethylphenyl)-2-(2-oxopyrrolidin-1-yl)acetamide
Clinical data
Routes of
administration
Oral
Legal status
Legal status
  • Unscheduled (US)
Identifiers
CAS Number 77191-36-7
ATC code none
PubChem CID 71157
Chemical data
Formula C14H18N2O2
Molar mass 246.305 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Nefiracetam is a nootropic antidementia drug of the racetam family[1].

Nefiracetam's cytoprotective actions are mediated by enhancement of GABAergic, cholinergic, and monoaminergic neuronal systems that give antiamnesia effects to the Alzheimer's type and cerebrovascular type of dementia.[2][3]

See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
  1. Murphy, Keith (22 July 2004). "Chronic Exposure of Rats to Cognition Enhancing Drugs Produces a Neuroplastic response" (PDF). Neuropsychopharmacology. Retrieved 1 September 2010. 
  2. Robinson RG, Jorge RE, Clarence-Smith K, Starkstein S (2009). "Double-blind treatment of apathy in patients with poststroke depression using nefiracetam". The Journal of Neuropsychiatry and Clinical Neurosciences. 21 (2): 144–51. doi:10.1176/appi.neuropsych.21.2.144. PMID 19622685. 
  3. Robinson RG, Jorge RE, Clarence-Smith K (2008). "Double-blind randomized treatment of poststroke depression using nefiracetam". The Journal of Neuropsychiatry and Clinical Neurosciences. 20 (2): 178–84. doi:10.1176/appi.neuropsych.20.2.178. PMID 18451188.